Status:
TERMINATED
Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Conditions:
Patients With Fungic Infections
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Purpose Invasive fungal infections cause significant morbidity and mortality in immunocompromised patients. Amphotericin B deoxycholate (AmB) is a polyene antifungal agent. The broad spectrum of acti...
Eligibility Criteria
Inclusion
- Patients with indications for AmB treatment
Exclusion
- Patients with acute kidney injury
- Hyperkalemia ≥5.2
- Hypersensibility to spironolactone
- HIV infection
- Pregnant women
- Solid organ transplant
- Hemodynamic instability
- CKDEPI ≤30ml/min/1.73m3
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01843309
Start Date
May 1 2013
End Date
March 1 2015
Last Update
July 7 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
México, State of Mexico, Mexico, 14000